ClinicalTrials.gg
Active, not recruitingNCT07086677Updated Jun 22, 2026

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

A Phase 1 interventional study of PG4 vaccine in Buffer 1 with low dose PA-001 and PG4 in Buffer 1 with low dose PA-002 in Streptococcus Pneumoniae, sponsored by Pfizer. Active, not recruiting at 20 sites in United States. Open to participants aged 65 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Pfizer · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
65 Years to 84 Years
Sex
All
01

Study summary

The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults.

Participants will receive either:

  • an experimental PG4 vaccine
  • a PG4 vaccine comparator
  • a standard 20vPnC vaccine comparator
  • placebo. A placebo does not have any medicine in it but looks just like the study medicine.

Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits.

At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.

02

Conditions studied

  • Streptococcus Pneumoniae
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Participants either with no history of ever receiving a pneumococcal vaccine or who have received a pneumococcal vaccine more than 5 years prior to vaccination in this study

Key Exclusion Criteria:

  • Participants with a history of microbiologically proven invasive disease caused by S pneumoniae.
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    PG4 vaccine with low dose adjuvant PA-001; dose schedule 1

    Biological: PG4 vaccine in Buffer 1 with low dose PA-001

  • Experimental
    PG4 vaccine with low dose adjuvant PA-001; dose schedule 2

    Biological: PG4 vaccine in Buffer 1 with low dose PA-001

  • Experimental
    PG4 vaccine with low dose adjuvant PA-002; dose schedule 1

    Biological: PG4 in Buffer 1 with low dose PA-002

  • Experimental
    PG4 vaccine with low dose adjuvant PA-002; dose schedule 2

    Biological: PG4 in Buffer 1 with low dose PA-002

  • Experimental
    PG4 vaccine with high dose adjuvant PA-001; dose schedule 1

    Biological: PG4 in Buffer 1 with high dose PA-001

  • Experimental
    PG4 vaccine with high dose adjuvant PA-001; dose schedule 2

    Biological: PG4 in Buffer 1 with high dose PA-001

  • Experimental
    PG4 vaccine with high dose adjuvant PA-002; dose schedule 1

    Biological: PG4 vaccine in Buffer 1 with high dose PA-002

  • Experimental
    PG4 vaccine with high dose adjuvant PA-002; dose schedule 2

    Biological: PG4 vaccine in Buffer 1 with high dose PA-002

  • Active comparator
    PG4 vaccine; dose schedule 1

    Biological: PG4 vaccine in Buffer 2 · Biological: Saline injection

  • Active comparator
    PG4 vaccine; dose schedule 2

    Biological: PG4 vaccine in Buffer 2 · Biological: Saline injection

  • Active comparator
    20vPnC; dose schedule 1

    Biological: 20-valent pneumococcal conjugate vaccine · Biological: Saline injection

  • Active comparator
    20vPnC; dose schedule 2

    Biological: 20-valent pneumococcal conjugate vaccine · Biological: Saline injection

Interventions

  • BiologicalPG4 vaccine in Buffer 1 with low dose PA-001

    Multivalent pneumococcal conjugate vaccine

  • BiologicalPG4 in Buffer 1 with low dose PA-002

    Multivalent pneumococcal conjugate vaccine

  • BiologicalPG4 in Buffer 1 with high dose PA-001

    Multivalent pneumococcal conjugate vaccine

  • BiologicalPG4 vaccine in Buffer 1 with high dose PA-002

    Multivalent pneumococcal conjugate vaccine

  • BiologicalPG4 vaccine in Buffer 2

    Multivalent pneumococcal conjugate vaccine

  • (20vPnC)

  • BiologicalSaline injection

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prespecified local reactions after each dose.

    Prespecified local reactions (redness, swelling, and pain at the injection site) occurring within 7 days of each dose administered in the study.

    Time frame: Within 7 days after each study intervention.

  2. Percentage of participants reporting prespecified systemic reactions after each dose.

    Prespecified systemic reactions (fever, vomiting, diarrhea, headache, fatigue, muscle pain, and joint pain) occurring within 7 days of each dose administered in the study.

    Time frame: Within 7 days after each study intervention.

  3. Percentage of participants reporting adverse events.

    Adverse Events (AEs) occurring from Dose 1 through 1 month after the last vaccination

    Time frame: From signing of the ICD to 1 month after last study intervention.

  4. Percentage of participants reporting serious adverse events.

    Serious Adverse Events (SAEs) occurring from Dose 1 through 6 months after the last vaccination.

    Time frame: From signing of the ICD to 6 months after the last study intervention.

  5. Percentage of participants reporting serious adverse events.

    Serious Adverse Events (SAEs) occurring from Dose 1 through 12 months after the last vaccination.

    Time frame: From signing of the ICD to 12 months after the last study intervention.

  6. Percentage of participants with abnormal hematology and chemistry laboratory values.

    Any abnormal hematology or chemistry laboratory values as compared to baseline within 2 weeks after each study intervention.

    Time frame: Within 2 weeks after each study intervention.

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Oct 21, 2027
CompletionEst.
Oct 21, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07086677
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jul 22, 2025
Primary completion
Oct 21, 2027 (estimated)
Completion
Oct 21, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion